Portal de investigação
Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults.
Autores da FMUP
Participantes de fora da FMUP
- Perez-de-Llano L
- Scelo G
- Tran TN
- Le TT
- Fagerås M
- Cosio BG
- Peters M
- Pfeffer PE
- Al-Ahmad M
- Al-Lehebi RO
- Altraja A
- Bergeron C
- Bjermer LH
- Bjerrum AS
- Bulathsinhala L
- Busby J
- Cano Rosales DJ
- Canonica GW
- Carter VA
- Charriot J
- Christoff GC
- Denton EJ
- Dorscheid DR
- Fernandez Sanchez MJ
- Gibson PG
- Goh CYY
- Heaney LG
- Heffler E
- Hew M
- Iwanaga T
- Katial R
- Koh MS
- Kuna P
- Larenas-Linnemann DES
- Lehtimäki L
- Mahboub B
- Martin N
- Matsumoto H
- Menzies-Gow AN
- Papadopoulos NG
- Popov TA
- Porsbjerg CM
- Patel P
- Rhee CK
- Sadatsafavi M
- Taillé C
- Torres-Duque CA
- Tsai MJ
- Ulrik CS
- Upham JW
- von Bülow A
- Wang E
- Wechsler ME
- Price DB
Unidades de investigação
Abstract
Rationale: There is no consensus on criteria to include in an asthma remission definition in real life. Factors associated with achieving remission after biologic initiation remain poorly understood. Objectives: To quantify the proportion of adults with severe asthma achieving multidomain-defined remission after biologic initiation and identify prebiologic characteristics associated with achieving remission that may be used to predict it. Methods: This was a longitudinal cohort study using data from 23 countries from the International Severe Asthma Registry. Four asthma outcome domains were assessed in the 1 year before and after biologic initiation. A priori-defined remission cutoffs were: 0 exacerbations/yr, no long-term oral corticosteroid (LTOCS), partly/well-controlled asthma, and percent predicted FEV(1) ? 80%. Remission was defined using two (exacerbations + LTOCS), three (+control or +lung function), and four of these domains. The association between prebiologic characteristics and postbiologic remission was assessed by multivariable analysis. Measurements and Main Results: A total of 50.2%, 33.5%, 25.8%, and 20.3% of patients met criteria for two-, three- (+control), three- (+lung function), and four-domain remission, respectively. The odds of achieving four-domain remission decreased by 15% for every additional 10 years of asthma duration (odds ratio, 0.85; 95% confidence interval, 0.73-1.00). The odds of remission increased in those with fewer exacerbations per year, lower LTOCS daily dose, better control, and better lung function before biologic initiation. Conclusions: One in five patients achieved four-domain remission within 1 year of biologic initiation. Patients with less severe impairment and shorter asthma duration at initiation had a greater chance of achieving remission after biologic treatment, indicating that biologic treatment should not be delayed if remission is the goal.
Dados da publicação
- ISSN/ISSNe:
- 1073-449X, 1535-4970
- Tipo:
- Article
- Páginas:
- 869-880
- PubMed:
- 38701495
American Journal of Respiratory and Critical Care Medicine American Thoracic Society
Documentos
- Não há documentos
Filiações
Keywords
- anti-IL4Ra; anti-IL5/5R; anti-IgE; exacerbation; lung function
Projetos associados
Prevalence and Characterisation of Asthma Patients According to Disease Severity in Portugal (EPI-ASTHMA) - NCT05169619
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (EPI-ASTHMA) . AstraZeneca . 2021
Effect of a Mobile App on Improving Asthma Control in Adolescents and Adults With Persistent Asthma: A Pilot Randomized Multicentre, Superiority Clinical Trial (mINSPIRERS) - NCT05129527
Investigador Principal: João de Almeida Lopes da Fonseca
Ensaio Clínico Académico (mINSPIRERS) . 2021
Utilização em estudos observacionais do Registo de Asma Grave Portugal.
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Observacional Académico (RAG) . 2020
Clinical Research Collaboration Severe Heterogenous Asthma Research collaboration, Patient-centered (CRC SHARP).
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (SHARP) . European Respiratory Society . 2021
Multidimensional phenotyping of severe asthma patients and its impact on disease control and therapeutic response - analysis from the Portuguese Severe Asthma Registry.
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (RAG-SPP-GSK) . SPPneumologia . 2022
BREATHE - An oBservational, pRimary data study to characterize severe AsThma pHenotypes and assEss disease burden across the EUCAN region.
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (RAG-AZ-BREATHE) . AstraZeneca . 2022
Efficiency in Spine Care ? Assessing outcomes and costs to inform healthcare improvement
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2022
Use of secondary data, health technology assessment methods and economic modelling applied to penicillin allergy
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
Using different data sources for the identification of asthma patients and those at high risk of adverse outcomes
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
Phenotypes of Chronic Diseases of the Airways: Towards Multidimensional Data -Driven Profiling
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
